Peter Kies Net Worth

The estimated Net Worth of Peter Kies is at least 2.91 百万$ dollars as of 15 May 2024. Mr. Kies owns over 4,771 units of Inovio Pharmaceuticals Inc stock worth over 176,385$ and over the last 19 years he sold INO stock worth over 1,586,238$. In addition, he makes 1,142,940$ as Chief Financial Officer at Inovio Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Kies INO stock SEC Form 4 insiders trading

Peter has made over 25 trades of the Inovio Pharmaceuticals Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 4,771 units of INO stock worth 31,250$ on 15 May 2024.

The largest trade he's ever made was exercising 70,511 units of Inovio Pharmaceuticals Inc stock on 26 February 2023 worth over 461,847$. On average, Peter trades about 16,451 units every 102 days since 2006. As of 15 May 2024 he still owns at least 26,929 units of Inovio Pharmaceuticals Inc stock.

You can see the complete history of Mr. Kies stock trades at the bottom of the page.

Peter Kies biography

Peter D. Kies serves as Chief Financial Officer of the Company. Mr. Kies has been employed as our Chief Financial Officer since 2002. From 1996 until joining us, he served as Chief Financial Officer for Newgen Results Corporation, and prior to that served as Controller for Cytel Corporation and as an auditor for Ernst & Young LLP. Mr. Kies holds a B.S. in Business Administration from United States International University in San Diego, California.

What is the salary of Peter Kies?

As the Chief Financial Officer of Inovio Pharmaceuticals Inc, the total compensation of Peter Kies at Inovio Pharmaceuticals Inc is 1,142,940$. There are 3 executives at Inovio Pharmaceuticals Inc getting paid more, with Jong Kim having the highest compensation of 2,588,530$.

How old is Peter Kies?

Peter Kies is 56, he's been the Chief Financial Officer of Inovio Pharmaceuticals Inc since 2002. There are 7 older and 7 younger executives at Inovio Pharmaceuticals Inc. The oldest executive at Inovio Pharmaceuticals Inc is Simon Benito, 75, who is the Independent Chairman of the Board.

What's Peter Kies's mailing address?

Peter's mailing address filed with the SEC is 10480 Wateridge Cir, San Diego, CA 92121, USA.

Insiders trading at Inovio Pharmaceuticals Inc

Over the last 20 years, insiders at Inovio Pharmaceuticals Inc have traded over 23,656,819$ worth of Inovio Pharmaceuticals Inc stock and bought 1,958,377 units worth 5,174,071$ . The most active insiders traders include Austin W & Greenhouse David...、Jong Joseph Kim、Felix Theeuwes. On average, Inovio Pharmaceuticals Inc executives and independent directors trade stock every 22 days with the average trade being worth of 745,390$. The most recent stock trade was executed by Michael John Sumner on 30 June 2024, trading 2,917 units of INO stock currently worth 19,106$.

What does Inovio Pharmaceuticals Inc do?

inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.

Complete history of Mr. Kies stock trades at Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc executives and stock owners

Inovio Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Jong Kim,
  President, Chief Executive Officer, Director
• Dr. J. Joseph Kim,
  CEO, Pres & Director
• Jacqueline Elizabeth Shea,
  Chief Operating Officer
• Peter Kies,
  Chief Financial Officer
• Laurent Humeau,
  Chief Scientific Officer
• Peter D. Kies,
  Chief Financial Officer
• Dr. Laurent M. Humeau,
  Chief Scientific Officer
• Dr. Jacqueline E. Shea Ph.D.,
  Chief Operating Officer
• David Weiner,
  Director
• Lota Zoth,
  Independent Director
• Simon Benito,
  Independent Chairman of the Board
• Ann Miller,
  Independent Director
• Wendy Yarno,
  Independent Director
• Jay Shepard,
  Independent Director
• Asli Gevgilili,
  Chief HR Officer
• Robert L. Crotty J.D.,
  Gen. Counsel
• Robert J. Juba Jr.,
  Sr. VP of Biological Manufacturing & Clinical Supply Management
• Dr. Jeffrey Skolnik,
  Sr. VP of Clinical Devel.
• Dr. Ami Shah Brown,
  Sr. VP of Regulatory Affairs
• Jessica C. Lee MS, MPH,
  Sr. VP of Clinical Operations & Global Integration
• E. J. Brandreth,
  Sr. VP of Quality Assurance
• Ben Matone,
  Director of Investor Relations
• Morton Collins,
  Director
• George Bickerstaff,
  Director
• Adel Mahmoud,
  Director
• Mark Bagarazzi,
  Chief Medical Officer
• Niranjan Sardesai,
  Sr. VP Research & Development
• Nancy Wysenski,
  Director
• Avtar S Dhillon,
  President & CEO
• Angel Cabrera,
  Director
• Austin W & Greenhouse David...,
  10% owner
• Dietmar P Rabussay,
  V.P. Research & Development
• George F. Iii Mc Hugh,
  Vice President, Operations
• Eugene A Larson,
  Director
• Felix Theeuwes,
  Director
• Robert S Goodenew,
  V.P. Corporate Development
• Michael Fons,
  VP, Corporate Development
• Kevin Rassas,
  Sr. VP Business Development
• Cheryl Jo White,
  Chief Medical Officer
• Tee Khiang Ng,
  Director
• Robert William Rieder,
  Director
• James L Heppell,
  Director
• David J Williams,
  Director
• Punit Dhillon,
  VP, Finance & Operations
• Riaz Amirali Bandali,
  Director
• Stephen Rietiker,
  Director
• Beng Lee Gan,
  Director
• Tazdin Esmail,
  Director
• Keith H Wells,
  Director
• Chin Cheong Chong,
  Director
• Roger D Dansey,
  Director
• Michael John Sumner,
  Chief Medical Officer